Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion
International Journal of Development Research
Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion
Received 29th April, 2020; Received in revised form 07th May, 2020; Accepted 27th June, 2020; Published online 30th July, 2020
Copyright © 2020, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled :“Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion” published by Vader et al. in Ophthalmology Retina 2020;4(6):576-587,which compared the efficacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of retinal vein occlusion– emergent macular edema. The study found that best-corrected visual acuity gain, anatomic outcomes, and safety were remarkably equivalent at 6 months in both treatment arms. However, the validation, extrapolation, and generalizability of the authors’ conclusions can be made only by statistical analyses including all the missing baseline factors mentioned by us in addition to the baseline characteristics already evaluated in this study.
